ADoBind MC001

ADoBind MC001 is an investigational **antibody-drug conjugate (ADC)** developed by Medicovestor for the treatment of **pancreatic cancer**. It represents a new generation of chemoimmunotherapy ADCs that incorporates several proprietary innovations: - Utilizes a **dimeric IgG1 antibody backbone** for enhanced **antibody-dependent cellular cytotoxicity (ADCC)**, engaging the immune system directly to kill cancer cells. - Engineered for **higher payload delivery** and **prolonged tumor engagement**, resulting in more efficient and sustained targeting of tumor cells. - Targets the **Folate receptor alpha (FRalpha)**, which is moderately to highly expressed in most pancreatic cancers. Binding to FRalpha can further induce higher expression, making tumor cells more susceptible to the therapy. - Functionally, it expands target expression by increasing effective antigen copy number, potentially allowing treatment even in tumors with low FRalpha expression. - Aims to overcome resistance mechanisms and the challenge of dense pancreatic tumor stroma with improved pharmacokinetics (e.g., extended half-life and exposure). ADoBind MC001 has received **FDA Orphan Drug Designation** for pancreatic cancer and is currently in IND-enabling/preclinical studies, with plans for Phase 1 clinical trials in early 2026[1][4][5][7][9][10].

Brand names

ADoBind MC001

Other names

Adobind MC-001